215 related articles for article (PubMed ID: 23603367)
41. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
42. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
Ismail MT; Fahmy DM; Elshmaa NS
Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
[TBL] [Abstract][Full Text] [Related]
44. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.
Baker WD; Pierce SR; Mills AM; Gehrig PA; Duska LR
Gynecol Oncol; 2017 Jul; 146(1):34-38. PubMed ID: 28427775
[TBL] [Abstract][Full Text] [Related]
45. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Arnes M; Hvingel B; Orbo A
Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
[TBL] [Abstract][Full Text] [Related]
46. Vaginal micronized progesterone versus the levonorgestrel-releasing intrauterine system for treatment of non-atypical endometrial hyperplasia: A randomized controlled trial.
Gezer Ş; Köle E; Aksoy L
Int J Gynaecol Obstet; 2023 May; 161(2):661-666. PubMed ID: 36527262
[TBL] [Abstract][Full Text] [Related]
47. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Ørbo A; Arnes M; Lyså LM; Straume B
Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
Xu Z; Yang B; Shan W; Liao J; Shao W; Wu P; Zhou S; Ning C; Luo X; Zhu Q; Zhang H; Ma F; Guan J; Chen X
Gynecol Oncol; 2023 Jul; 174():133-141. PubMed ID: 37182434
[TBL] [Abstract][Full Text] [Related]
49. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
[TBL] [Abstract][Full Text] [Related]
50. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
51. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.
Hampton NR; Rees MC; Lowe DG; Rauramo I; Barlow D; Guillebaud J
Hum Reprod; 2005 Sep; 20(9):2653-60. PubMed ID: 15905289
[TBL] [Abstract][Full Text] [Related]
52. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.
Fu Y; Zhuang Z
Int J Clin Exp Pathol; 2014; 7(10):6419-29. PubMed ID: 25400720
[TBL] [Abstract][Full Text] [Related]
53. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
Philip S; Taylor AH; Konje JC; Habiba M
J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
[TBL] [Abstract][Full Text] [Related]
54. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
Vereide AB; Kaino T; Sager G; Ørbo A;
Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
[TBL] [Abstract][Full Text] [Related]
55. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.
Gardner FJ; Konje JC; Bell SC; Abrams KR; Brown LJ; Taylor DJ; Habiba M
Gynecol Oncol; 2009 Sep; 114(3):452-6. PubMed ID: 19576623
[TBL] [Abstract][Full Text] [Related]
56. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
[TBL] [Abstract][Full Text] [Related]
57. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a levonorgestrel-releasing intrauterine system for treating endometrial hyperplasia in patients with polycystic ovary syndrome.
Lin M; Xu X; Wang Y; Hu Y; Zhao Y
Gynecol Obstet Invest; 2014; 78(1):41-4. PubMed ID: 24852134
[TBL] [Abstract][Full Text] [Related]
59. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
Depypere H; Inki P
Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
[TBL] [Abstract][Full Text] [Related]
60. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
